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Letters to the EditorTo the Editor:
We have read with interest the article by Baid-Agrawal et al. [1].
The authors deﬁne occult hepatitis C virus (HCV) infection ‘‘as
presence of HCV RNA in peripheral blood mononuclear cells
(PBMC) in the absence of HCV RNA in serum, irrespective of the
anti-HCV status’’. This deﬁnition includes two different types of
patients: those who have presumably recovered of an HCV infec-
tion (anti-HCV positive) and those without serological evidences
of a prior exposure to HCV (anti-HCV negative) and thus, they
should be studied separately. The concept of occult HCV infection
is still a matter of debate, and in our opinion, this is because both
types of occult HCV infection are not considered as separate enti-
ties. In this regard, when authors afﬁrm that several studies have
failed to detect HCV RNA in PBMC in various clinical settings,
most of the cited articles deal with anti-HCV positive cases and
only three analyzed anti-HCV negative patients. By contrast,
occult HCV infection has been detected by different investigators
in anti-HCV negative patients with cryptogenic liver disease,
hepatocellular carcinoma or onco-hematological disorders [2–6].
The authors have found a low prevalence of HCV infection in
the study population (3.6% in hemodialysis and 4.8% in kidney
transplant). Furthermore, the authors indicate that the reported
overall HCV prevalence in Germany is 0.3%. Taking into account
this low incidence of HCV, the prevalence of occult HCV infection
found in this study (0.25% in haemodialysis and 0.5% in kidney
transplant) cannot be considered negligible.
For HCV RNA detection in PBMC, integrity of the isolated RNA
and the amount used for viral RNA detection are crucial parame-
ters especially when very low amounts of intracellular HCV RNA
are expected. This information has not been provided by the
authors and it is important to be sure that no false negative
results have been obtained due to poor quality of the total RNA
used in HCV RNA detection. Furthermore, although TMA is the
most sensitive commercial assay for HCV RNA detection, it has
been shown that ultracentrifugation of 2 ml of serum to concen-
trate viral particles prior to RT-PCR, allows HCV RNA detection in
TMA negative samples [7]. So, in the absence of a liver biopsy, to
discard the existence of occult HCV infection, testing for HCV RNA
in serum after ultracentrifugation and detection of anti-HCV core
antibodies [8] must be performed as these are the only detectable
serum markers in some patients who are HCV RNA negative in
PBMC but who have an occult HCV infection in the liver. As this
has not been performed, prevalence of occult HCV infection in
the studied patients may be underestimated.
In the discussion section, the authors argue against the exis-
tence of occult HCV infection stating that in renal or liver trans-
plants of anti-HCV positive patients, clearance of the virus
before transplantation is associated with a lack of reinfection
Open access under CC BY-NC-ND license.Journal of Hepatologyafter transplantation. However, reinfection of liver graft in occult
HCV infection has been demonstrated [9].
On the other hand, the fact that patients with occult HCV in
this study present normal liver function tests in the follow-up
does not imply that they do not have liver disease, as this type
of patients usually have normal ALT levels due to their
immunological status. Thus, it cannot be assumed that occult
HCV infection has no clinical relevance in these patients unless
absence of liver damage is demonstrated by transient
elastography (as liver biopsy may not be performed in this type
of patients due to possible complications).
The authors suggest that the high prevalence of occult HCV
infection documented in other studies may be due to cross-
contamination during HCV RNA detection. However, in these
studies, cross-contamination was discarded because positivity
to HCV RNA in liver or peripheral blood mononuclear cells was
conﬁrmed by amplifying a different region of the HCV genome
and by cloning, sequencing and phylogenetic analysis of the
PCR products.
Finally, we completely disagree with the assertion that
presence of HCV RNA in PBMC in the absence of anti HCV should
be called ‘‘occult detection of HCV RNA’’ rather than ‘‘occult HCV
infection’’, because these patients have both positive and nega-
tive HCV RNA strands in liver and in PBMC and have circulating
viral particles with the same physicochemical characteristics
than those found in patients with chronic HCV infection [7]. Fur-
thermore, HCV RNA persists a long time in serum and PBMC of
patients with occult HCV infection [10], indicating an ongoing
HCV infection.
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Reply to: ‘‘Underestimation of occult hepatitis C virus infection
in chronic haemodialysis and kidney transplant patients’’
To the Editor:
We thank Carreno et al. for their interest in our study regarding
occult hepatitis C virus (HCV) infection in haemodialysis and
kidney transplant patients and appreciate their comments as
they reﬂect the complexity and controversy of data available on
the topic of occult HCV infection [1]. Their group has provided
evidence on the presence of occult HCV infection in patients on
chronic haemodialysis in Spain [2]. However, it must be noted
that several studies have failed to conﬁrm occult HCV infection
under various circumstances using particularly sensitive tests
[3–5]. Reports on detection of HCV proteins in patients with
occult HCV infection need to be interpreted with caution in
respect of the methods used and results of other studies [3].
The method used by Carreno et al. included serial dilutions of
the isolated RNA that cannot be considered a gold standard due
to the limit of detection of HCV RNA by an in-house reverse tran-
scription PCR method [5]. We used the highly sensitive HCV RNA
transcription-mediated ampliﬁcation (TMA) assay for the detec-
tion of HCV RNA in peripheral blood mononuclear cells (PBMC).
Furthermore, the authors tested for occult HCV infection only in
selected haemodialysis patients with abnormal liver enzyme
values, whereas we did a prevalence study in a large number
of haemodialysis and kidney transplant patients, irrespective of
their liver function status, in order to study the potential role of
routine screening for occult HCV infection in these patients. In
response to the authors’ criticism of not studying anti-HCV posi-
tive and anti-HCV negative patients separately, we would like to
clarify that we did look at both HCV-positive and HCV-negative
cases separately and did not ﬁnd any prevalence of occult HCV
infection in any of the HCV-positive cases. The results are shown
in Table 2 and Fig. 1 of our paper [1].
The authors argue that ‘‘for HCV RNA detection in PBMC, integ-
rity of the isolated RNA and the amount used for viral RNA detec-
tion are crucial parameters, especially when very low amounts of
intracellular HCV RNA are expected’’. They further argue that ‘‘this
information has not been provided by the authors and it is impor-
tant to be sure that no false negative results have been obtained
due to the poor quality of the total RNA used in HCV RNA detec-
tion’’. This argument is true for HCV RNA detection by real-time
PCR in combination with extraction methods for isolation of total
nucleic acids. However, in this study, we used the isothermal TMA
assay combined with a HCV-speciﬁc RNA capture method in one
single reaction tube. Since cellular DNA and RNA were washed
out before starting the ampliﬁcation steps, total RNA cannot be
used for standardization of the sample input. With parallel
processing of an internal control, we were able tomonitor the efﬁ-
ciency of RNA capture and ampliﬁcation in each single reaction
tube. The main issue concerning HCV RNA detection in PBMC
was to reach at least the same analytical sensitivity compared to
HCV RNA detection in serum or plasma in order to exclude
false negative results. Therefore, we used a minimum input of
2.5 million PBMC representing approximately 2.0 to 2.5 ml
of whole blood, which corresponds to approximately 1.0 ml of
plasma (compared to 0.5 mlused forHCVRNAdetection in serum).
As far as sufﬁcient numbers of PBMC were available for individual
samples, a higher PBMC input could be used in order to improve
the analytical sensitivity for HCV RNA detection in the PBMC.
We fully agree with the authors that the incidence of occult
HCV infection found in our haemodialysis and kidney transplant
patients is not absolutely negligible. However, as also elaborated
in our paper, we would like to emphasize that the positive test
found in all our patients was weak positive. Furthermore, none
of these patients has developed any signs of liver disease nor
positive HCV RNA, even at the most recent mean follow up of
54 months in the two patients alive, suggesting that the weak
positive test for occult HCV infection found in these patients at
the onset may have been false positive. Furthermore, regarding
the authors’ argument that the lack of clinical relevance of occult
HCV infection cannot be assumed in these patients unless
absence of liver damage is demonstrated by transient elastogra-
phy, we would like to state that although non-invasive methods
like transient elastography have been shown to be reliable for the
diagnosis of cirrhosis, they are less accurate than liver biopsy in
discriminating different ﬁbrosis stages even in the non-transplant
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